Trial · NCT01317472
The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux
NCT01317472, Not applicable, Terminated, Indiana University; results first posted 2019-10-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux. Trials, record NCT01317472. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01317472
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux
- NCT number
- NCT01317472
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 11 participants, actual
- Lead sponsor
- Indiana University
- Conditions
- Laryngopharyngeal Reflux
- Interventions
- dexlansoprazole, Placebo
- First posted
- 2011-03-17
- Last updated
- 2019-10-01
- Results first posted
- 2019-10-01
- Limitations and caveats
- very poor recruitment. patients were not willing to enter study because they did not want to take a chance on receiving placebo.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Reflux Symptom Index (RSI) | Baseline to 2 months | The Reflux Symptom Index (RSI) is a 9-item measure with each symptom rated from 0 (no problem) to 5 (severe problem), for a total possible range of 0 (no problem) to 45 (severe problem). An RSI of \>13 is considered to be abnormal. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Reflux Symptom Index (RSI) | Baseline to 2 months | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Reflux Symptom Index (RSI) | Dexlansoprazole | 18 | Standard Deviation 3.95 | units on a scale | |
| Change in Reflux Symptom Index (RSI) | Sugar Pill | 13 | Standard Deviation 4.54 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dexlansoprazole | 9 | |
| Overall Study | STARTED | Sugar Pill | 2 | |
| Overall Study | COMPLETED | Dexlansoprazole | 7 | |
| Overall Study | COMPLETED | Sugar Pill | 2 | |
| Overall Study | NOT COMPLETED | Dexlansoprazole | 2 | |
| Overall Study | NOT COMPLETED | Sugar Pill | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dexlansoprazole | 0 | 9 |
| Total, all-cause mortality | Sugar Pill | 0 | 2 |
| Total, other adverse events | Dexlansoprazole | 0 | 9 |
| Total, other adverse events | Sugar Pill | 0 | 2 |
| Total, serious adverse events | Dexlansoprazole | 0 | 9 |
| Total, serious adverse events | Sugar Pill | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Dexlansoprazole vs Sugar Pill: deaths from any cause | Trial comparisons |
| Dexlansoprazole vs Sugar Pill: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01317472
GET https://conductscience.org/api/trials/v1/NCT01317472/registered